【drug-news】【资讯翻译】诺华着眼在日本市场投放雷珠单抗
发布于 2012-09-09 · 浏览 2081 · IP 北京北京
这个帖子发布于 12 年零 249 天前，其中的信息可能已发生改变或有所发展。
http://www.fiercepharma.com/story/novartis-eyes-japan-potential-new-use-lucentis/2012-09-07
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Novartis ($NVS), whose blockbuster eye drug Lucentis has been fighting a price war with off-label use of Avastin, has data supporting a new indication for the drug and will take that with an application to Japan, a market Big Pharma is finding many ways to love.
The company this week said that new data found that an average of three Lucentis (ranibizumab) injections improved visual acuity in patients with myopic choroidal neovascularization (CNV), Pharma Times reports, and 29% of patients didn't need any treatment beyond an initial injection. The Swiss drug giant said it would take that data to the European Medicines Agency and to authorities in Japan by the end of the year.
Lucentis has been a major revenue generator for the company. It is producing annualized revenue of more than $2 billion already, Reuters points out. But it has been hitting some tough competition of late from doctors using Avastin off-label for treating wet age-related macular degeneration (AMD). Novartis recently offered an undisclosed discount to a cluster of healthcare providers in the U.K. who had insisted that Avastin was a better deal. They bit on the new price.
That Novartis, which markets the drug outside the U.S., wants to go to Japan as well as the EU with the new application is not a big surprise. While the EU has been tough on drug spending and some countries are cutting way back there, Japan is seen as a more promising market.
Regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere. The government's pricing policies have eased up. Meanwhile, the island nation's growing aging population is strengthening demand for drugs. Result? Fast-growing sales at a time when other regions are suffering.
Novartis has already said it intends to launch lots of new drugs there over the next few years. It already has a 4.4% market share and is in the top 10 but says it is shooting for being among the top three drug suppliers there.
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Novartis ($NVS), whose blockbuster eye drug Lucentis has been fighting a price war with off-label use of Avastin, has data supporting a new indication for the drug and will take that with an application to Japan, a market Big Pharma is finding many ways to love.
The company this week said that new data found that an average of three Lucentis (ranibizumab) injections improved visual acuity in patients with myopic choroidal neovascularization (CNV), Pharma Times reports, and 29% of patients didn't need any treatment beyond an initial injection. The Swiss drug giant said it would take that data to the European Medicines Agency and to authorities in Japan by the end of the year.
Lucentis has been a major revenue generator for the company. It is producing annualized revenue of more than $2 billion already, Reuters points out. But it has been hitting some tough competition of late from doctors using Avastin off-label for treating wet age-related macular degeneration (AMD). Novartis recently offered an undisclosed discount to a cluster of healthcare providers in the U.K. who had insisted that Avastin was a better deal. They bit on the new price.
That Novartis, which markets the drug outside the U.S., wants to go to Japan as well as the EU with the new application is not a big surprise. While the EU has been tough on drug spending and some countries are cutting way back there, Japan is seen as a more promising market.
Regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere. The government's pricing policies have eased up. Meanwhile, the island nation's growing aging population is strengthening demand for drugs. Result? Fast-growing sales at a time when other regions are suffering.
Novartis has already said it intends to launch lots of new drugs there over the next few years. It already has a 4.4% market share and is in the top 10 but says it is shooting for being among the top three drug suppliers there.
最后编辑于 2022-10-09 · 浏览 2081
6 收藏点赞
